← Back to Clinical Trials
Recruiting NCT06492967

NCT06492967 LatAm-FINGERS Initiative for Cognitive Change

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06492967
Status Recruiting
Phase
Sponsor Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Condition Alzheimer Disease
Study Type INTERVENTIONAL
Enrollment 1,200 participants
Start Date 2021-09-01
Primary Completion 2027-12-01

Trial Parameters

Condition Alzheimer Disease
Sponsor Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Study Type INTERVENTIONAL
Phase N/A
Enrollment 1,200
Sex ALL
Min Age 60 Years
Max Age 77 Years
Start Date 2021-09-01
Completion 2027-12-01
Interventions
Systematic Lifestyle InterventionFlexible Lifestyle Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Currently, 40% of global dementia cases can be prevented through lifestyle changes, with Latin America having a 56% potential reduction due to its high-risk factors. At the moment, there are no medications that halt the clinical expression of dementia. LatAm-FINGERS, a multicenter study across 12 Latin American countries, aims to study the feasibility of an intervention modifying lifestyle in individuals aged 60 to 77 at risk of dementia. Success could influence public policy on clinical care for older adults.

Eligibility Criteria

Inclusion Criteria * Age: 60-77 years. * Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score \> 6. * Mini-Mental State Examination (MMSE) z score between 0 and -1.5 OR * CERAD Word List Learning Task (10 word x 3 repetitions) \< 0 z score OR * CERAD (delayed word list recall) \< z score \< 0 Exclusion Criteria * MMSE \< 20 * Dementia * Any medical condition that affects the participant's safety. * Severe osteoarticular problems that preclude the implementation of the physical activity intervention outlined in the protocol, such as, for example: osteoarthrosis of the knee(s), coxofemoral, or other. * Significant neurological disease, including dementia, cognitive impairment, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head injury with persistent neurological sequelae or structural brain abnormalities, ma

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology